WO2008055159A4 - Flash photolysis therapy for regulation of physiological function - Google Patents

Flash photolysis therapy for regulation of physiological function Download PDF

Info

Publication number
WO2008055159A4
WO2008055159A4 PCT/US2007/083009 US2007083009W WO2008055159A4 WO 2008055159 A4 WO2008055159 A4 WO 2008055159A4 US 2007083009 W US2007083009 W US 2007083009W WO 2008055159 A4 WO2008055159 A4 WO 2008055159A4
Authority
WO
WIPO (PCT)
Prior art keywords
light
photo
reactive compound
cells
myocardial
Prior art date
Application number
PCT/US2007/083009
Other languages
French (fr)
Other versions
WO2008055159A2 (en
WO2008055159A3 (en
Inventor
Rodolphe P Katra
Original Assignee
Medtronic Inc
Rodolphe P Katra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic Inc, Rodolphe P Katra filed Critical Medtronic Inc
Priority to EP07863660A priority Critical patent/EP2079523A2/en
Publication of WO2008055159A2 publication Critical patent/WO2008055159A2/en
Publication of WO2008055159A3 publication Critical patent/WO2008055159A3/en
Publication of WO2008055159A4 publication Critical patent/WO2008055159A4/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0622—Optical stimulation for exciting neural tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/362—Heart stimulators
    • A61N1/3629—Heart stimulators in combination with non-electric therapy

Abstract

Flash photolysis therapy is used to enhance cellular function, such as abnormal myocardial or renal function. A photo-reactive compound is administered to cells requiring therapy. A light stimulus is applied to the photo-reactive compound to cause desired intracellular activity when the photo-reactive compound is activated. The activated compound can, for example, affect intracellular calcium concentration, to cause forced contraction or relaxation in the muscle tissue.

Claims

24AMENDED CLAIMS received by the International Bureau on 07 November 2008) (07.11.2008)
1. A therapeutic flash photolysis system comprising: means for administering a photo-reactive compound to a patient, the photo-reactive compound being inert until activated by light to form an active compound that regulates a physiological function of the patient; and means for emitting light at a wavelength that activates the photo-reactive compound; means for sensing a physiologic parameter; and means for controlling the means for emitting light as a function of the physiologic parameter, wherein the sensing means comprises means for sensing heartbeats; and the controlling means comprises means for timing delivery of light pulses from the emitting means coordinated with sensed heartbeats.
2. A system according to claim 1 wherein the photo-reactive compound undergoes a chemical reaction prior to activation.
3. A system according to claim 1 , wherein the photo-reactive compound is administered in a membrane-permeant form.
4. A method according to claim 4, wherein the photo-reactive compound is administered in an acetoxymethyl ester form.
5. A system according to claim 4, wherein photo-reactive compound is convertible to an active form capable of responding to the light through an enzymatic reaction within the cells.
6. A system according to claim 5, wherein the photo-reactive compound is transportable out of the cells following activation by light.
7. A system according to claim 1 , wherein the photo-reactive compound comprises a calcium sensitive compound.
8. A system according to claim 7, wherein the photo-reactive compound is capable of manipulating intracellular calcium concentration when activated by light.
9. A system according to claim 8, wherein the photo-reactive compound has an affinity for calcium that increases in response to being activated.
10. A system according to claim 8, wherein the photo-reactive compound has an affinity for calcium that decreases in response to being activated.
11. A system according to claim 1 , wherein the means for administering the photo-reactive compound comprises a pump.
12. A system according to claim 1 , wherein the means for emitting light delivers the light to cells within a region of an organ.
13. A system according to claim 12, wherein the means for emitting light delivers the light in a scanning pattern to the cells.
14. A system according to claim 12, wherein the cells comprise myocardial cells.
15. A system according to claim 14, wherein the photo-reactive compound forces myocardial contraction when activated.
16. A system according to claim 15, wherein the means for emitting light delivers a light pulse during systole. 26
17. A system according to claim 14, wherein the photo-reactive compound forces myocardial relaxation when activated.
18. A system according to claim 17, wherein the means for emitting light delivers a light pulse during diastole.
19. A system according to claim 1 , wherein the drug delivery means comprises means for delivering the drug to myocardial cells.
20. A system according to claim 19, wherein the drug delivery means comprises a drug pump.
21. A system according to claim 20, wherein the drug delivery means comprises an implantable, refillable drug pump.
22. A system according to claim 21 , wherein the drug delivery means further comprises a delivery conduit having a proximal end connected to the drug pump and a distal end positionable proximate the myocardial cells.
23. A system according to claim 19, wherein the light delivery device comprises: a light source; and a light guide for directing light from the light source to the myocardial cells.
24. A system according to claim 23, wherein the light delivery device comprises a light distribution element at a distal end of the light guide.
25. A system according to claim 24, wherein the light distribution element is 27
movable to scan light from the light guide onto the myocardial cells.
26. A system according to claim 25, wherein the light distribution element is rotatable.
27. A system according to claim 1 , wherein the physiologic parameter comprises EGM signals.
28. A system according to claim 1 , wherein the physiologic parameter comprises one of myocardial electrical, chemical and mechanical activity.
29. A system according to claim 19, wherein the photo-reactive compound is administered in a membrane permeant form.
30. A system according to claim 29, wherein the photo-reactive compound is administered in an acetoxymethyl ester form.
31. A system according to claim 30, wherein photo-reactive compound is convertible to an active form capable of responding to the light stimulus through an enzymatic reaction within the cells.
32. A system according to claim 31 , wherein the photo-reactive compound is transportable out of the cells following activation by the light stimulus.
33. A system according to claim 19, wherein the photo-reactive compound comprises a calcium sensitive compound.
34. A system according to claim 33, wherein the photo-reactive compound is capable of manipulating intracellular calcium concentration when activated by the light stimulus. 28
35. A system according to claim 34, wherein the photo-reactive compound has an affinity for calcium that increases in response to being activated.
36. A system according to claim 34, wherein the photo-reactive compound has an affinity for calcium that decreases in response to being activated.
37. A system according to claim 19, wherein the light delivery device delivers the light stimulus in a scanning pattern to the cells.
38. A system according to claim 19, wherein the cells of the patient comprise myocardial cells.
39. A system according to claim 38, wherein the photo-reactive compound forces myocardial contraction when activated.
40. A system according to claim 39, wherein the light stimulus comprises a light pulse delivered during systole.
41. A system according to claim 38, wherein the photo-reactive compound forces myocardial relaxation when activated.
42. A system according to claim 41 , wherein the light stimulus comprises a light pulse delivered during diastole.
43. A system for controlling cardiac filling, the system comprising: a drug delivery device for administering a photo-reactive compound to myocardial cells; and a light activation device for applying a light stimulus to the photo-reactive compound to cause at least one of forced myocardial relaxation and forced myocardial contraction. 29
44. A system according to claim 43, wherein the drug delivery device comprises an implantable, refutable drug pump.
45. A system according to claim 44, wherein the drug delivery device further comprises a delivery conduit having a proximal end connected to the drug pump and a distal end positionable proximate the cells.
46. A system according to claim 43, wherein the light activation device comprises: a light source; and a light guide for directing light from the light source to the cells.
47. A system according to claim 46, wherein the light activation device further comprises a light distribution element at a distal end of the light guide.
48. A system according to claim 47, wherein the light distribution element is movable to scan light from the light guide onto the cells.
49. A system according to claim 48, wherein the light distribution element is rotatable.
50. A system according to claim 43 and further comprising: a sensor for sensing a physiologic parameter; and a controller for controlling light activation device as a function of the physiologic parameter sensed.
51. A system according to claim 50, wherein physiologic parameter comprises one of myocardial electrical, chemical and mechanical activity.
52. A system according to claim 43, wherein the photo-reactive compound is administered in a membrane permeant form. 30
53. A system according to claim 52, wherein the photo-reactive compound is administered in an acetoxymethyl ester form.
54. A system according to claim 52, wherein the photo-reactive compound is convertible to an active form capable of responding to the light stimulus through an enzymatic reaction within the cells.
55. A system according to claim 52, wherein the photo-reactive compound is transportable out of the cells following activation by the light stimulus.
56. A system according to claim 43, wherein the photo-reactive compound comprises a calcium sensitive compound.
57. A system according to claim 1 , wherein the physiologic parameter comprises a hemodynamic parameter.
58. A system according to claim 57 wherein the hemodynamic parameter comprises pressure.
59. A system according to claim 1 wherein the physiological parameter comprises acceleration.
60. A system according to claim 1 wherein the physiologic parameter comprises bioimpedance.
PCT/US2007/083009 2006-10-30 2007-10-30 Flash photolysis therapy for regulation of physiological function WO2008055159A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07863660A EP2079523A2 (en) 2006-10-30 2007-10-30 Flash photolysis therapy for regulation of physiological function

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86341906P 2006-10-30 2006-10-30
US60/863,419 2006-10-30

Publications (3)

Publication Number Publication Date
WO2008055159A2 WO2008055159A2 (en) 2008-05-08
WO2008055159A3 WO2008055159A3 (en) 2008-10-30
WO2008055159A4 true WO2008055159A4 (en) 2008-12-31

Family

ID=39345052

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/083009 WO2008055159A2 (en) 2006-10-30 2007-10-30 Flash photolysis therapy for regulation of physiological function

Country Status (2)

Country Link
EP (1) EP2079523A2 (en)
WO (1) WO2008055159A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435276B2 (en) * 2006-02-27 2013-05-07 Thomas Perez Method and apparatus for the combined application of light therapy, optic diagnosis, and fluid to tissue
GB0816501D0 (en) * 2008-09-10 2008-10-15 Imp Innovations Ltd Photo-ionic pacemakers
US8951296B2 (en) 2012-06-29 2015-02-10 Medtronic Ardian Luxembourg S.A.R.L. Devices and methods for photodynamically modulating neural function in a human

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298018A (en) * 1992-08-14 1994-03-29 Pdt Cardiovascular, Inc. Method for treating cardiovascular disease through adjunctive photodynamic therapy
US5445608A (en) * 1993-08-16 1995-08-29 James C. Chen Method and apparatus for providing light-activated therapy
AT403990B (en) * 1995-11-24 1998-07-27 Nagypal Tibor Dipl Ing Dr DEVICE FOR THE PHOTODYNAMIC TREATMENT OF LIVING BEINGS OR. ORGANS THE SAME
AU2002218742A1 (en) * 2000-07-11 2002-01-21 Johns Hopkins University Application of photochemotherapy for the treatment of cardiac arrhythmias
US6811562B1 (en) * 2000-07-31 2004-11-02 Epicor, Inc. Procedures for photodynamic cardiac ablation therapy and devices for those procedures
US20050101997A1 (en) * 2003-11-12 2005-05-12 Reddy Vivek Y. Arrangements and methods for determining or treating cardiac abnormalities and inconsistencies
US20070244524A1 (en) * 2006-04-12 2007-10-18 Jihong Qu Method and device for photoreactive therapy and diagnosis

Also Published As

Publication number Publication date
WO2008055159A2 (en) 2008-05-08
EP2079523A2 (en) 2009-07-22
WO2008055159A3 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
US7481759B2 (en) Systems and methods for treatment of coronary artery disease
US8805492B2 (en) Method and apparatus for delivering combined electrical and drug therapies
US8934968B2 (en) Neurostimulation and coronary artery disease treatment
US8126560B2 (en) Stimulation lead for stimulating the baroreceptors in the pulmonary artery
JP5011392B2 (en) Percutaneous nerve stimulation device that regulates cardiovascular function
US6845267B2 (en) Systems and methods for modulation of circulatory perfusion by electrical and/or drug stimulation
JP5010683B2 (en) Percutaneous nerve stimulation device that regulates cardiovascular function
US5087243A (en) Myocardial iontophoresis
US8024050B2 (en) Lead for stimulating the baroreceptors in the pulmonary artery
US8818501B2 (en) Method and system for treating acute heart failure by neuromodulation
US20040106954A1 (en) Treatment of congestive heart failure
US20110160697A1 (en) Device and method for enhanced subcutaneous insulin absorption
US20080167696A1 (en) Stimulus waveforms for baroreflex activation
CN103298521A (en) Implant tool and improved electrode design for minimally invasive procedure
US20100249860A1 (en) External cardiac stimulation patch
US8219192B2 (en) Method and apparatus for transcutaneous cardioprotective pacing
JP2008523892A5 (en)
JP2008521566A (en) Method and system for providing therapy in the pericardial space
AU2007290672A1 (en) Integrated catheter and pulse generator
EP2103327A3 (en) Switch polarity pacing to improve cardiac resynchronization therapy
WO2008154660A1 (en) Hepatic electrical stimulation
US7621906B2 (en) Method and apparatus to deliver drug and pacing therapy for treatment of cardiac disorders
WO2008055159A4 (en) Flash photolysis therapy for regulation of physiological function
US20100292745A1 (en) Method and apparatus for safety control during cardiac pacing mode transition
EP2201980A1 (en) Implantable tissue stimulator

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07863660

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007863660

Country of ref document: EP